Q (sonnet): Is KRAS G12C more aggressive than G12D?

═ answer (success)
I can help you explore how KRAS G12C and G12D cohorts compare in cBioPortal, but I want to flag upfront: **cBioPortal's database does not contain a validated measure of mutation-specific "aggressiveness."** That kind of claim requires statistical comparison (survival analysis, clinical outcome testing) between the two variant groups within a specific cancer type — it's not a fact stored anywhere, and I won't fabricate a conclusion.

What I *can* do is show you the data needed to investigate this yourself, but this requires picking a specific cancer type first, since KRAS G12C vs G12D prevalence and behavior differs substantially by tumor type (e.g., G12C dominates in lung adenocarcinoma, G12D dominates in pancreatic and colorectal cancer).

A few clarifying questions before I run anything:

1. **Which cancer type** are you interested in? (e.g., lung adenocarcinoma, pancreatic, colorectal)
2. **Which outcome** do you mean by "aggressive" — overall survival, progression-free survival, tumor stage/grade at diagnosis, or something else?

Once you specify, I can:
- Pull the variant counts and frequencies for G12C vs G12D in that cohort
- Set up a **Group Comparison** (G12C-mutant vs G12D-mutant samples) with the **Survival tab** pre-loaded, so you can see Kaplan-Meier curves and let the portal's own statistical engine compute the log-rank p-value and hazard ratio — rather than me guessing at significance

Would you like to proceed with a specific cancer type (e.g., lung adenocarcinoma, where G12C is clinically most relevant), or would you like me to check which studies have enough KRAS G12C and G12D cases to make such a comparison meaningful?